MGNX Stock Analysis

MGNX -  USA Stock  

USD 21.89  0.30  1.39%

The big decline in price over the last few months for Macrogenicsmay encourage investors to take a closer look at the firm as it is trading at a share price of 21.89 on 2,166,100 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Macrogenics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.96. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Macrogenics partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Macrogenics stock analysis report makes it easy to digest most publicly released information about Macrogenics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. MGNX stock analysis module also helps to analyze the Macrogenics price relationship with some important fundamental indicators such as market cap and management efficiency.

MGNX Stock Analysis Notes

About 91.0% of the company shares are owned by institutional investors. The book value of Macrogenics was now reported as 5.84. The company has Price/Earnings To Growth (PEG) ratio of 0.05. Macrogenics recorded a loss per share of 2.5. The entity had not issued any dividends in recent years. MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 370 people. To find out more about Macrogenics contact Scott Koenig at 301 251 5172 or learn more at http://www.macrogenics.com.

Macrogenics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Macrogenics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Macrogenics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Macrogenics generates negative expected return over the last 90 days
Macrogenics has high historical volatility and very poor performance
The company reported the previous year's revenue of 108.08 M. Net Loss for the year was (136.29 M) with loss before overhead, payroll, taxes, and interest of (88.32 M).
Macrogenics currently holds about 343.18 M in cash with (96.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.72.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from www.fiercebiotech.com: Zai Lab to pay MacroGenics 25M upfront with 1.4B in potential biobucks for bispecific immuno-oncology antibodies - FierceBiotech

Macrogenics Upcoming and Recent Events

Earnings reports are used by Macrogenics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Macrogenics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of July 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

MGNX Largest EPS Surprises

Earnings surprises can significantly impact Macrogenics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-05-06
2014-03-31-0.08-0.12-0.0450 
2019-05-01
2019-03-31-0.8738-0.99-0.116213 
2020-05-05
2020-03-31-1.04-0.910.1312 
View All Earnings Estimates

Macrogenics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Macrogenics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Macrogenics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Macrogenics specific information freely available to individual and institutional investors to make a timely investment decision.
18th of May 2021
Submission of Matters to a Vote of Security Holders
View
29th of April 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
1st of April 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
9th of March 2021
Unclassified Corporate Event
View
25th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View
12th of February 2021
Unclassified Corporate Event
View
11th of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
View

Macrogenics Thematic Classifications

In addition to having Macrogenics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

MGNX Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Macrogenics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Macrogenics backward and forwards among themselves. Macrogenics' institutional investor refers to the entity that pools money to purchase Macrogenics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Bellevue Group AgCommon SharesM192 M
Blackrock IncCommon Shares5.8 M184.2 M
Ra Capital Management LpCommon Shares4.9 M157.1 M
Wasatch Advisors IncCommon Shares4.1 M130.7 M
Vanguard Group IncCommon Shares3.8 M122.1 M
State Street CorpCommon Shares2.7 M85 M
Consonance Capital Management LpCommon Shares2.5 M78.7 M
Note, although Macrogenics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

MGNX Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.3 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Macrogenics's market, we take the total number of its shares issued and multiply it by Macrogenics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

MGNX Profitablity

Macrogenics' profitability indicators refer to fundamental financial ratios that showcase Macrogenics' ability to generate income relative to its revenue or operating costs. If, let's say, Macrogenics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Macrogenics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Macrogenics' profitability requires more research than a typical breakdown of Macrogenics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (126.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (126.67) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.27.
Last ReportedProjected for 2021
Return on Investment(49.78) (53.71) 
Return on Average Assets(0.39) (0.40) 
Return on Average Equity(0.51) (0.55) 
Return on Invested Capital(0.86) (0.88) 
Return on Sales(1.24) (1.34) 

Management Efficiency

The entity has return on total asset (ROA) of (24.42) % which means that it has lost $24.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (50.37) %, meaning that it created substantial loss on money invested by shareholders. Macrogenics management efficiency ratios could be used to measure how well macrogenics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -53.71 in 2021. Return on Average Assets is likely to drop to -0.4 in 2021. Macrogenics Revenue to Assets are fairly stable at the moment as compared to the past year. Macrogenics reported Revenue to Assets of 0.28 in 2020. Total Assets Per Share is likely to rise to 6.91 in 2021, whereas Total Assets are likely to drop slightly above 343.1 M in 2021.
Last ReportedProjected for 2021
Book Value per Share 5.64  5.92 
Enterprise Value over EBIT(9.00) (9.71) 
Enterprise Value over EBITDA(9.44) (9.69) 
Price to Book Value 4.34  4.07 
Tangible Assets Book Value per Share 7.22  7.41 
Enterprise Value1.1 B962 M
Tangible Asset Value378.7 M343.1 M

Technical Drivers

As of the 19th of June, Macrogenics secures the mean deviation of 3.09, and Risk Adjusted Performance of (0.06). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Macrogenics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Macrogenics, which can be compared to its peers in the industry. Please verify Macrogenics mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Macrogenics is priced some-what accurately, providing market reflects its recent price of 21.89 per share. Given that Macrogenics has jensen alpha of (0.52), we recommend you to check Macrogenics's last-minute market performance to make sure the company can sustain itself at a future point.

Macrogenics Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. The Weighted Moving Average calculates a weight for each value in Macrogenics price series with the more recent values given greater weights. View also all equity analysis or get more info about weighted moving average overlap studies indicator.

Macrogenics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Macrogenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Macrogenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Macrogenics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biotech Target N V 2 days ago via Macroaxis 
Purchase by Biotech Target N V of 100000 shares of Macrogenics
Biotech Target N V over a week ago via Macroaxis 
Macrogenics exotic insider transaction detected
Ezio Bonvini over a month ago via Macroaxis 
Exercise or conversion by Ezio Bonvini of 5000 shares of Macrogenics subject to Rule 16b-3
Jay Siegel over a month ago via Macroaxis 
Acquisition by Jay Siegel of 15000 shares of Macrogenics subject to Rule 16b-3
Thomas Spitznagel over two months ago via Macroaxis 
Exercise or conversion by Thomas Spitznagel of 5000 shares of Macrogenics subject to Rule 16b-3
Ezio Bonvini over two months ago via Macroaxis 
Sale by Ezio Bonvini of 17 shares of Macrogenics
Jeffrey Peters over three months ago via Macroaxis 
Exercise or conversion by Jeffrey Peters of 21749 shares of Macrogenics subject to Rule 16b-3
Jeffrey Peters over three months ago via Macroaxis 
Acquisition by Jeffrey Peters of 90000 shares of Macrogenics subject to Rule 16b-3
Obrien Federica F over three months ago via Macroaxis 
Acquisition by Obrien Federica F of 30000 shares of Macrogenics subject to Rule 16b-3
James Karrels over three months ago via Macroaxis 
Exercise or conversion by James Karrels of 5000 shares of MacroGenics subject to Rule 16b-3
Eric Risser over three months ago via Macroaxis 
Exercise or conversion by Eric Risser of 500 shares of MacroGenics subject to Rule 16b-3
Eric Risser over six months ago via Macroaxis 
Exercise or conversion by Eric Risser of 500 shares of MacroGenics subject to Rule 16b-3

Macrogenics Predictive Daily Indicators

Macrogenics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Macrogenics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Macrogenics Forecast Models

Macrogenics time-series forecasting models is one of many Macrogenics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Macrogenics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Macrogenics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Macrogenics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MGNX shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Macrogenics. By using and applying MGNX Stock analysis, traders can create a robust methodology for identifying MGNX entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(16.14) (17.42) 
EBITDA Margin(1.12) (1.21) 
Gross Margin 0.90  0.89 
Profit Margin(1.24) (1.34) 
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 370 people.

Current MGNX Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MGNX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MGNX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
34.43Buy7Odds
Macrogenics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most MGNX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MGNX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Macrogenics, talking to its executives and customers, or listening to MGNX conference calls.
MGNX Analyst Advice Details

MGNX Stock Analysis Indicators

Macrogenics stock analysis indicators help investors evaluate how Macrogenics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Macrogenics shares will generate the highest return on investment. By understating and applying Macrogenics stock analysis, traders can identify Macrogenics position entry and exit signals to maximize returns.
Quick Ratio6.61
Fifty Two Week Low18.16
Revenue Growth23.40%
Shares Short Prior Month4.23M
Average Daily Volume Last 10 Day1.37M
Average Daily Volume In Three Month741.25k
Shares Percent Shares Out5.88%
Gross Margins-82.68%
Short Percent Of Float6.04%
Forward Price Earnings-7.60
Float Shares54.12M
Fifty Two Week High36.48
Enterprise Value To Ebitda-12.74
Fifty Day Average30.03
Two Hundred Day Average26.56
Enterprise Value To Revenue14.77
Additionally, see Stocks Correlation. Note that the Macrogenics information on this page should be used as a complementary analysis to other Macrogenics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Macrogenics Stock analysis

When running Macrogenics price analysis, check to measure Macrogenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Macrogenics is operating at the current time. Most of Macrogenics' value examination focuses on studying past and present price action to predict the probability of Macrogenics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Macrogenics' price. Additionally, you may evaluate how the addition of Macrogenics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
The market value of Macrogenics is measured differently than its book value, which is the value of MGNX that is recorded on the company's balance sheet. Investors also form their own opinion of Macrogenics' value that differs from its market value or its book value, called intrinsic value, which is Macrogenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Macrogenics' market value can be influenced by many factors that don't directly affect Macrogenics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Macrogenics' value and its price as these two are different measures arrived at by different means. Investors typically determine Macrogenics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Macrogenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.